|Min SIP Amount||Not Supported|
|NAV||₹10.61 (14 Aug 2020)|
|Fund Started||28 Sep 2017|
|Fund Size||₹347 Cr|
|Ipca Laboratories Ltd.||Healthcare||Equity||7.1%|
|ICICI Bank Ltd.||Financial||Equity||6.6%|
|Multi Commodity Exchange India||Financial||Equity||6.2%|
|Gujarat Gas Ltd.||Chemicals||Equity||6.2%|
|Axis Bank Ltd.||Financial||Equity||4.8%|
|Eicher Motors Ltd.||Automobile||Equity||4.6%|
|Crompton Greaves Consumer Electricals Ltd.||Cons Durable||Equity||4.2%|
UTI Focussed Equity Fund Series IV (1104 Days) Direct Growth is a Equity Mutual Fund Scheme launched by Axis Mutual Fund. This scheme was made available to investors on 28 Sep 2017. Vetri Subramaniam, Sachin Trivedi is the Current Fund Manager of UTI Focussed Equity Fund Series IV (1104 Days) Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹347 Cr and the Latest NAV as of 14 Aug 2020 is ₹10.61.
The UTI Focussed Equity Fund Series IV (1104 Days) Direct Growth is rated Moderately High risk. Minimum SIP Investment is set to 500.
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of listed companies. The scheme will without any capitalization bias endeavor to invest in either growth stocks or value stocks or both. The Scheme will normally hold upto 30 stocks in the portfolio. The Scheme does not guarantee/indicate any returns. There can be no assurance that the Schemeâ??s objectives will be achieved.